Extended Data Fig. 2: Change in tumor size from baseline in cohort 4A + 4B in the full analysis set. | Nature Medicine

Extended Data Fig. 2: Change in tumor size from baseline in cohort 4A + 4B in the full analysis set.

From: First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial

Extended Data Fig. 2: Change in tumor size from baseline in cohort 4A + 4B in the full analysis set.

Patients included were those with baseline and post-baseline measurements (n = 61); patients classified as non-CR/non-PD are not included. One patient had no evaluable CLDN18.2 status. aThis patient had no evaluable CPS status. CLDN18.2, claudin 18 isoform 2; CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease.

Back to article page